BioArctic AB (BRCTF)
20.00
+6.34
(+46.45%)
USD |
OTCM |
Nov 14, 15:33
BioArctic Enterprise Value: 1.160B for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 1.160B |
| November 12, 2024 | 1.104B |
| November 11, 2024 | 1.119B |
| November 08, 2024 | 1.107B |
| November 07, 2024 | 1.166B |
| November 06, 2024 | 1.166B |
| November 05, 2024 | 1.135B |
| November 04, 2024 | 1.135B |
| November 01, 2024 | 1.252B |
| October 31, 2024 | 1.252B |
| October 30, 2024 | 1.252B |
| October 29, 2024 | 1.252B |
| October 28, 2024 | 1.247B |
| October 25, 2024 | 1.225B |
| October 24, 2024 | 1.225B |
| October 23, 2024 | 1.272B |
| October 22, 2024 | 1.272B |
| October 21, 2024 | 1.316B |
| October 18, 2024 | 1.316B |
| October 17, 2024 | 1.316B |
| October 16, 2024 | 1.241B |
| October 15, 2024 | 1.297B |
| October 14, 2024 | 1.297B |
| October 11, 2024 | 1.297B |
| October 10, 2024 | 1.297B |
| Date | Value |
|---|---|
| October 09, 2024 | 1.297B |
| October 08, 2024 | 1.297B |
| October 07, 2024 | 1.297B |
| October 04, 2024 | 1.328B |
| October 03, 2024 | 1.328B |
| October 02, 2024 | 1.328B |
| October 01, 2024 | 1.328B |
| September 30, 2024 | 1.328B |
| September 27, 2024 | 1.371B |
| September 26, 2024 | 1.371B |
| September 25, 2024 | 1.371B |
| September 24, 2024 | 1.446B |
| September 23, 2024 | 1.446B |
| September 20, 2024 | 1.446B |
| September 19, 2024 | 1.446B |
| September 18, 2024 | 1.447B |
| September 17, 2024 | 1.447B |
| September 16, 2024 | 1.447B |
| September 13, 2024 | 1.447B |
| September 12, 2024 | 1.447B |
| September 11, 2024 | 1.386B |
| September 10, 2024 | 1.471B |
| September 09, 2024 | 1.471B |
| September 06, 2024 | 1.363B |
| September 05, 2024 | 1.363B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.104B
Minimum
Nov 12 2024
2.553B
Maximum
Jun 30 2023
1.872B
Average
1.871B
Median
May 28 2024
Enterprise Value Benchmarks
| Abliva AB | 11.86M |
| Oncopeptides AB | -- |
| BioInvent International AB | 215.05M |
| Hansa Biopharma AB | 278.10M |
| Camurus AB | 3.067B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.415M |
| Revenue (Quarterly) | 4.673M |
| Total Expenses (Quarterly) | 11.78M |
| EPS Diluted (Quarterly) | -0.0722 |
| Gross Profit Margin (Quarterly) | 90.35% |
| Profit Margin (Quarterly) | -137.3% |
| Earnings Yield | -0.49% |
| Normalized Earnings Yield | -0.4869 |